Physician profile
Yezid Mora
NPI 1366465122
$5,094.09
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $1,673 · 2021: $662 · 2022: $1,120 · 2023: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $854.58 | 2019-2023 | Fasenra, Breztri |
| Glaxosmithkline, LLC. | $431.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.15 | 2019-2023 | Jardiance |
| Amgen INC. | $410.58 | 2020-2023 | Repatha, Otezla |
| Lilly USA, LLC | $400.65 | 2019-2023 | Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $397.78 | 2019-2022 | |
| Novo Nordisk INC | $397.53 | 2019-2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.32 | 2019 | |
| Merck Sharp & Dohme LLC | $255.16 | 2019-2020 | |
| Amarin Pharma, INC. | $204.84 | 2020 | |
| Sanofi-Aventis U.S. LLC | $178.18 | 2019-2020 | |
| Allergan, INC. | $140.18 | 2019-2020 | |
| Pfizer INC. | $114.83 | 2019-2020 | |
| Horizon Therapeutics Plc | $113.98 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $93.24 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $80.38 | 2019-2020 | |
| Exact Sciences Corporation | $59.39 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $57.04 | 2022 | |
| Astellas Pharma US INC | $42.89 | 2019-2022 | |
| Abbvie INC. | $41.94 | 2022 | |
| Shield Therapeutics INC | $35.61 | 2023 | Accrufer |
| Abbott Laboratories | $21.67 | 2021 | |
| Hologic Sales and Service, LLC | $18.16 | 2021 | |
| Circassia INC. | $15.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yezid Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.